Daniel Rabinowitz, who serves as Secretary and Chief Legal Officer at Natera, Inc. (NASDAQ:NTRA), executed a sale of company stock on February 3, 2026. The transaction involved 1,334 shares of common stock sold at a price of $230.768 per share, producing proceeds of roughly $307,844.
After completing that sale, Rabinowitz remains a significant shareholder, retaining direct ownership of 223,813 shares of Natera. Company filings indicate the sale was undertaken specifically to satisfy tax liabilities that arose upon the vesting of Restricted Stock Units (RSUs).
Alongside the insider transaction, Natera released preliminary operational results for the fourth quarter that management characterized as strong. The company expects revenue growth of nearly 40% year-over-year for the period, outpacing analyst expectations cited by the company. Test volume for the quarter rose by approximately 17% compared with the same period a year earlier.
Following the preliminary results, Canaccord Genuity left its Buy rating on Natera intact and reiterated a price target of $285.00.
Natera also disclosed multiple clinical and regulatory developments. The company submitted a premarket approval application to the U.S. Food and Drug Administration for its Signatera CDx test, intended to detect molecular residual disease in patients with bladder cancer. That regulatory filing is supported by data from the phase 3 IMvigor011 clinical trial, which the company says demonstrated significant improvements in survival for patients treated with atezolizumab.
In transplant diagnostics, Natera has finished enrollment for the ACES-EMB trial, which assesses whether the Prospera Heart test can replace invasive biopsies in heart transplant monitoring. The trial enrolled over 300 patients across 17 U.S. transplant centers, according to the company.
Additional clinical activity includes Natera's plan to present results from its EXPAND trial at the Society for Maternal-Fetal Medicine meeting in February 2026; that study focuses on fetal genetic screening. The company also announced a new AI model designed to enhance cancer recurrence risk assessment by integrating multiple data types to improve its Signatera MRD test.
The insider sale, according to filings, was a tax-driven disposition tied to vested RSUs and did not alter Rabinowitz's substantial ongoing ownership position in the company.